Literature DB >> 20103641

Exon-based clustering of murine breast tumor transcriptomes reveals alternative exons whose expression is associated with metastasis.

Martin Dutertre1, Magali Lacroix-Triki, Keltouma Driouch, Pierre de la Grange, Lise Gratadou, Samantha Beck, Stefania Millevoi, Jamal Tazi, Rosette Lidereau, Stephan Vagner, Didier Auboeuf.   

Abstract

In the field of bioinformatics, exon profiling is a developing area of disease-associated transcriptome analysis. In this study, we performed a microarray-based transcriptome analysis at the single exon level in mouse 4T1 primary mammary tumors with different metastatic capabilities. A novel bioinformatics platform was developed that identified 679 genes with differentially expressed exons in 4T1 tumors, many of which were involved in cell morphology and movement. Of 152 alternative exons tested by reverse transcription-PCR, 97 were validated as differentially expressed in primary tumors with different metastatic capability. This analysis revealed candidate progression genes, hinting at variations in protein functions by alternate exon usage. In a parallel effort, we developed a novel exon-based clustering analysis and identified alternative exons in tumor transcriptomes that were associated with dissemination of primary tumor cells to sites of pulmonary metastasis. This analysis also revealed that the splicing events identified by comparing primary tumors were not aberrant events. Lastly, we found that a subset of differentially spliced variant transcripts identified in the murine model was associated with poor prognosis in a large clinical cohort of patients with breast cancer. Our findings illustrate the utility of exon profiling to define novel theranostic markers for study in cancer progression and metastasis.

Entities:  

Mesh:

Year:  2010        PMID: 20103641     DOI: 10.1158/0008-5472.CAN-09-2703

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  34 in total

1.  Cotranscriptional exon skipping in the genotoxic stress response.

Authors:  Martin Dutertre; Gabriel Sanchez; Marie-Cécile De Cian; Jérôme Barbier; Etienne Dardenne; Lise Gratadou; Gwendal Dujardin; Catherine Le Jossic-Corcos; Laurent Corcos; Didier Auboeuf
Journal:  Nat Struct Mol Biol       Date:  2010-10-24       Impact factor: 15.369

2.  Alternative transcription exceeds alternative splicing in generating the transcriptome diversity of cerebellar development.

Authors:  Sharmistha Pal; Ravi Gupta; Hyunsoo Kim; Priyankara Wickramasinghe; Valérie Baubet; Louise C Showe; Nadia Dahmane; Ramana V Davuluri
Journal:  Genome Res       Date:  2011-06-28       Impact factor: 9.043

3.  Splicing switch of an epigenetic regulator by RNA helicases promotes tumor-cell invasiveness.

Authors:  Etienne Dardenne; Sandra Pierredon; Keltouma Driouch; Lise Gratadou; Magali Lacroix-Triki; Micaela Polay Espinoza; Eleonora Zonta; Sophie Germann; Hussein Mortada; Jean-Philippe Villemin; Martin Dutertre; Rosette Lidereau; Stéphan Vagner; Didier Auboeuf
Journal:  Nat Struct Mol Biol       Date:  2012-09-30       Impact factor: 15.369

Review 4.  A methodological approach to unravel organ-specific breast cancer metastasis.

Authors:  Sébastien Nola; Soraya Sin; Florian Bonin; Rosette Lidereau; Keltouma Driouch
Journal:  J Mammary Gland Biol Neoplasia       Date:  2012-05-25       Impact factor: 2.673

5.  Anoctamin 6 differs from VRAC and VSOAC but is involved in apoptosis and supports volume regulation in the presence of Ca2+.

Authors:  C A Juul; S Grubb; K A Poulsen; T Kyed; N Hashem; I H Lambert; E H Larsen; E K Hoffmann
Journal:  Pflugers Arch       Date:  2014-01-14       Impact factor: 3.657

6.  SRSF1-Regulated Alternative Splicing in Breast Cancer.

Authors:  Olga Anczuków; Martin Akerman; Antoine Cléry; Jie Wu; Chen Shen; Nitin H Shirole; Amanda Raimer; Shuying Sun; Mads A Jensen; Yimin Hua; Frédéric H-T Allain; Adrian R Krainer
Journal:  Mol Cell       Date:  2015-10-01       Impact factor: 17.970

7.  Integrin α3β1 controls mRNA splicing that determines Cox-2 mRNA stability in breast cancer cells.

Authors:  Sita Subbaram; Scott P Lyons; Kimberly B Svenson; Sean L Hammond; Lorena G McCabe; Sridar V Chittur; C Michael DiPersio
Journal:  J Cell Sci       Date:  2014-01-16       Impact factor: 5.285

8.  Liposome-siRNA-peptide complexes cross the blood-brain barrier and significantly decrease PrP on neuronal cells and PrP in infected cell cultures.

Authors:  Bruce Pulford; Natalia Reim; Aimee Bell; Jessica Veatch; Genevieve Forster; Heather Bender; Crystal Meyerett; Scott Hafeman; Brady Michel; Theodore Johnson; A Christy Wyckoff; Gino Miele; Christian Julius; Jan Kranich; Alan Schenkel; Steven Dow; Mark D Zabel
Journal:  PLoS One       Date:  2010-06-14       Impact factor: 3.240

9.  Exon-level transcriptome profiling in murine breast cancer reveals splicing changes specific to tumors with different metastatic abilities.

Authors:  Amandine Bemmo; Christel Dias; April A N Rose; Caterina Russo; Peter Siegel; Jacek Majewski
Journal:  PLoS One       Date:  2010-08-06       Impact factor: 3.240

Review 10.  The relevance of the TGF-β Paradox to EMT-MET programs.

Authors:  Chevaun D Morrison; Jenny G Parvani; William P Schiemann
Journal:  Cancer Lett       Date:  2013-03-05       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.